Indivior PLC INDV

LON: INDV | ISIN: GB00BN4HT335   31/05/2024
1.445,00 GBX (+0,84%)
(+0,84%)   31/05/2024

23 mei 2024 · Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance · Persbericht

25 april 2024 · Indivior Announces Q1 2024 Financial Results · Persbericht

11 maart 2024 · Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone · Persbericht

29 februari 2024 · Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation · Persbericht

22 februari 2024 · Indivior Announces Q4 / FY 2023 Financial Results · Persbericht

9 november 2023 · Indivior Announces Q3 2023 Financial Results · Persbericht

11 oktober 2023 · Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals · Persbericht

26 september 2023 · Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada · Persbericht

21 augustus 2023 · Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims · Persbericht

27 juli 2023 · Indivior Announces Q2/H1 2023 Financial Results · Persbericht

14 juni 2023 · Indivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence · Persbericht

12 juni 2023 · Indivior to Commence Trading on Nasdaq · Persbericht

2 juni 2023 · Indivior Reaches Agreement with States' Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation Claims · Persbericht

25 mei 2023 · Indivior To Participate In Upcoming Investor Conferences · Persbericht

23 mei 2023 · Indivior PLC Form 20-F Registration Statement for Additional US Listing Now Available; Trading on NASDAQ Expected to Commence on June 12th · Persbericht

23 mei 2023 · Indivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl · Persbericht

27 april 2023 · Indivior Announces Q1 2023 Financial Results · Persbericht

25 april 2023 · Indivior To Participate In Bank of America Global Healthcare Conference 2023 · Persbericht

2 maart 2023 · Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc. · Persbericht

16 februari 2023 · FY 2022 Financial Results Announced · Persbericht

Mijn selecties